<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT2015101024453N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2017-09-09</date_registration>
      <primary_sponsor>School of Rehabilitation of Tehran University of Medical Sciences,</primary_sponsor>
      <public_title>The Effects of Dry Needling on the Trigger Finger</public_title>
      <acronym>TF</acronym>
      <scientific_title>The Effects of Dry Needling on, Ultrasonographic features , Pain, Hand functional performance  in Patients with  Trigger Finger  compare to the  Control Group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-05-29</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/20638</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: In this study, in addition to the examination of ultrasound of the tendon diameter and the thickness of the pulley, the effectiveness of the hand is measured through a questionnaire.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Trigger finger.</hc_freetext>
      <i_freetext>Intervention 1: In the intervention group,Dry needling  is done by the needle making company DongBang of South Korea. the location of the tendon prominence through the touch and, according to, the surface anatomical landmark . the tendon are acupuncture needles of 16 mm diameter, 8 mm in three lateral medial directions, and in parallel with the tendon with a 45 ° angle of inclination and 10 turns in the direction And counterclockwise. In the control group, the patient is advised to reduce his activity and return to assessment for seven days. Intervention 2: Control group: Give enough time to the body to take care of the body repair. Provide advice to the patient to reduce the activity of his or her hands and not carry out heavy work for one week after the initial assessment.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan></results_IPD_plan>
      <results_IPD_description></results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hosain Bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Piche Shemiran, Enghelab Ave,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>789456123</zip>
        <telephone>+98 21 7753 3393</telephone>
        <email>hbagheri@tums.ac.ir</email>
        <affiliation>School of Rehabilitation of Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hosain bagheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Piche Shemiran, Enghelab Ave,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>789456123</zip>
        <telephone>+98 21 7753 3393</telephone>
        <email>hbagheri@tums.ac.ir</email>
        <affiliation>School of Rehabilitation of Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inclusion criteria: 1-Not having Fear of Needle&#13;
2- Getting in one of the three groups of trigger finger disorder (having three symptoms of pain and&#13;
Tenderness at the position of A1 pulley, feeling pain and discomfort when flexing and extending finger, and nodule palpation&#13;
3. At least 4 weeks of history of the disease&#13;
4. Disorders of movement during finger movement&#13;
5. Did not have previous surgery in the affected area&#13;
6. The health of the proximal joints&#13;
7- Ability to perform the desired tests&#13;
8.  No pacemaker&#13;
9) Absence of ulcers in the target area&#13;
10. Not having coagulation problems&#13;
 11.  Have Satisfaction to participate in the study and willingness to cooperate.&#13;
12. Do Not having rheumatoid arthritis.&#13;
 13. Not taking analgesic and sedative medications after the onset of intervention&#13;
 14. No drug use&#13;
16. The absence of neurological diseases&#13;
Exclusion Criteria: &#13;
 1. Any damage to the skin of the infection and trauma during the study&#13;
2. Unwillingness to continue cooperation&#13;
3. Perform any surgeries during the research&#13;
4. Fear of the needle during the intervention stages&#13;
5. Any trauma and fracture during the evaluation process&#13;
6. Any hematoma and edema</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria></exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M65.3</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Trigger finger, Nodular tendinous disease</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>In the intervention group,Dry needling  is done by the needle making company DongBang of South Korea. the location of the tendon prominence through the touch and, according to, the surface anatomical landmark . the tendon are acupuncture needles of 16 mm diameter, 8 mm in three lateral medial directions, and in parallel with the tendon with a 45 ° angle of inclination and 10 turns in the direction And counterclockwise. In the control group, the patient is advised to reduce his activity and return to assessment for seven days.</i_keyword>
      <i_keyword>Control group: Give enough time to the body to take care of the body repair. Provide advice to the patient to reduce the activity of his or her hands and not carry out heavy work for one week after the initial assessment.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Thickness of pulley. Timepoint: before and seven day after intervention. Method of measurement: Musculoskeletal ultrasonography in millimeters.</prim_outcome>
      <prim_outcome>Tendon Diameter. Timepoint: before and seven day after intervention. Method of measurement: Musculoskeletal ultrasonography in millimeters.</prim_outcome>
      <prim_outcome>Power of pinch. Timepoint: before and seven day after intervention. Method of measurement: Kilograms - pinch gauge.</prim_outcome>
      <prim_outcome>Disabilities of the Arm, Shoulder and Hand. Timepoint: before and seven day after intervention. Method of measurement: Disabilities of Hand - DASH.</prim_outcome>
      <prim_outcome>Power of gripe. Timepoint: before and seven day after intervention. Method of measurement: Kilograms - dynamometer.</prim_outcome>
      <prim_outcome>Pain. Timepoint: before and seven day after intervention. Method of measurement: visual analog scale.</prim_outcome>
      <prim_outcome>Quinnell grading. Timepoint: before and seven day after intervention. Method of measurement: Quinnell grading system.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Pain. Timepoint: Immediately after needling. Method of measurement: VAS.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>School of Rehabilitation of Tehran University of Medical Sciences,</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-05-29</approval_date>
        <contact_name>Tehran University of Medical Scienses</contact_name>
        <contact_address>The Committee on Ethics in the Research of the Faculty of Nursing and Midwifery and the Faculty of Rehabilitation, Ms. Zahra Tavakol Tehran  Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
